A Phase III Study Comparing Low Dose Cyclosporine, Methotrexate And Prednisone Versus Standard Dose Cyclosporine and Methotrexate As Graft Versus Host Disease Prophylaxis In Myeloablative Allogeneic Stem Cell Transplantation (ALLG BM10 trial) in patients with haematological malignancies.

Trial Profile

A Phase III Study Comparing Low Dose Cyclosporine, Methotrexate And Prednisone Versus Standard Dose Cyclosporine and Methotrexate As Graft Versus Host Disease Prophylaxis In Myeloablative Allogeneic Stem Cell Transplantation (ALLG BM10 trial) in patients with haematological malignancies.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Prednisone (Primary) ; Ciclosporin; Ciclosporin
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2016 Status changed from not yet recruiting to completed.
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top